RecruitingNot ApplicableNCT04368039
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
Sponsor
Nicholas Breitborde
Enrollment
20 participants
Start Date
Dec 4, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.
Eligibility
Min Age: 15 YearsMax Age: 35 Years
Plain Language Summary
Simplified for easier understanding
This study is testing whether breathing high levels of oxygen in a normal-pressure environment (normobaric oxygen therapy) can improve symptoms in people who have recently experienced their first episode of psychosis. The idea is that oxygen therapy may support brain healing and improve thinking and mood in the early stages of psychotic illness.
**You may be eligible if:**
- You are 15 to 35 years old
- You have been diagnosed with a schizophrenia-spectrum disorder or a mood disorder with psychotic features
- Your first psychotic episode began less than 5 years ago
- You estimate average intelligence or above (IQ estimated above 70)
- You are a non-smoker and have not smoked for the past 6 months
- You have no thoughts of suicide or self-harm in the past month
**You may NOT be eligible if:**
- You have a history of intellectual disability
- You have been smoking recently (within the last 6 months)
- You have active suicidal thoughts or behavior
- You have medical conditions that may be worsened by supplemental oxygen therapy
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICENormobaric Oxygen
40% FiO2 for 4 weeks
DEVICEPlacebo
21% FiO2 for 4 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04368039
Related Trials
Cognitive Strategies in Early Psychosis 2
NCT072630221 location
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
NCT072883336 locations
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
NCT0710109418 locations
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
NCT0728856739 locations
A Study of Brenipatide in Adult Participants With Schizophrenia
NCT07410507102 locations